Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
synapse health, and involved in learning and memory. The therapy may also influence the immune system toward anti-inflammatory efficacy. Preclinical studies have already demonstrated Bryostatin's potential to address cognitive impairment in other neurodegenerative disorders such as Alzheimer's disease, traumatic brain injury,
and Fragile X syndrome. MS may represent a new indication to ameliorate cognitive impairment.